Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | ITGAL | P20701 | 17/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 16/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 16/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392277 | 1.00 | TMEM97 (0.54) | TMEM97ITGALITGB2ICAM1FNTA | |
| SCHEMBL2390313 | 0.90 | TMEM97 (0.59) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2390306 | 0.90 | TMEM97 (0.59) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2397897 | 0.85 | TMEM97 (0.58) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2393184 | 0.85 | TMEM97 (0.58) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2393177 | 0.85 | TMEM97 (0.58) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2393122 | 0.82 | TMEM97 (0.55) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2392723 | 0.81 | ITGAL (0.64) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2392729 | 0.81 | ITGAL (0.64) | TMEM97ITGALITGB2ICAM1 | |
| SCHEMBL2392446 | 0.81 | TMEM97 (0.62) | TMEM97ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | TMEM97 3442/4885ITGAL 74/4885ITGB2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.